Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 7/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24427335 | 0.77 | CYP2A6 (0.38) | EPHX2 | |
| SCHEMBL15108909 | 0.70 | CHRNA7 (0.51) | EPHX2MAPT | |
| SCHEMBL26633206 | 0.68 | EPHX2 (0.39) | EPHX2 | |
| SCHEMBL2463958 | 0.68 | CYP11B1 (0.57) | CYP11B1CYP11B2IDO1ASIC3POLB | |
| SCHEMBL21662554 | 0.68 | IDO1 (0.58) | CYP11B1CYP11B2IDO1ASIC3POLB | |
| SCHEMBL24427339 | 0.68 | MAPK14 (0.38) | CYP3A4EPHX2 | |
| SCHEMBL2457300 | 0.67 | CYP11B1 (0.47) | CYP11B1CYP11B2IDO1ASIC3POLB | |
| SCHEMBL22845366 | 0.66 | EPHX2 (0.50) | EPHX2 | |
| SCHEMBL26265591 | 0.65 | CYP11B1 (0.85) | CYP11B1CYP11B2IDO1ASIC3POLB | |
| SCHEMBL2458494 | 0.65 | DYRK1A (0.50) | CYP11B1CYP11B2IDO1ASIC3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | CYP11B1 111/4885CYP11B2 107/4885PRMT5 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.